

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2010

(Rs.in Lakhs)

	Particulars	STANDALONE					CONSOLIDATED				
		Quarter ended		Half Year ended		Year Ended	Quarter ended		Half Year ended		Year Ended
		30.09.2010	30.09.2009	30.09.2010	30.09.2009	31.03.2010	30.09.2010	30.09.2009	30.09.2010	30.09.2009	31.03.2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
1	(a) Net Sales/Income from operations (Net of Excise Duty)	25330	22287	51584	42564	92928	25531	22534	51881	43117	94161
	(b) Other Operating Income	355	362	631	1304	1737	361	212	489	1430	2232
	Total Income	25685	22649	52215	43868	94665	25892	22746	52370	44547	96393
2	<u>Expenditure:</u>										
	a. (Increase) / Decrease in Stock-in-Trade and Work-in-Progress	877	(2473)	(547)	(4856)	(9924)	855	(2607)	(755)	(4657)	(9339)
	b. Consumption of Raw Material	9455	8946	21033	19523	39521	9407	9043	21015	19598	39658
	c. Purchase of Traded Goods					0					0
	d. Employees Cost	1862	1654	3599	3441	6846	1982	1765	3849	3683	7334
	e. Depreciation	1327	1305	2638	2591	5145	1328	1306	2640	2593	5148
	f. Other Expenditure										
	- Manufacturing Expenses	2518	1703	4642	3415	7174	2599	1826	4837	3545	7456
	- Other expenses	2140	1887	4371	3541	8126	2265	1975	4615	3748	8527
	g. Total	18179	13022	35736	27655	56888	18436	13308	36201	28510	58784
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	7506	9627	16479	16213	37777	7456	9438	16169	16037	37609
4	Other Income	596	314	1086	599	1333	563	338	1021	548	1202
5	Profit before Interest & Exceptional Items (3+4)	8102	9941	17565	16812	39110	8019	9776	17190	16585	38811

	Percentage of shares (as a % of the total share capital of the company)	52.20%	52.98%	52.20%	52.98%	52.36%		52.20%	52.98%	52.20%	52.98%	52.36%
--	---	---------------	--------	---------------	--------	--------	--	---------------	--------	---------------	--------	--------

Statement of Assets and Liabilities:

(Rs.in Lakhs)

	Particulars	STANDALONE			CONSOLIDATED		
		Half Year ended		Year ended	Half Year ended		Year ended
		30.09.2010	30.09.2009	31.03.2010	30.09.2010	30.09.2009	31.03.2010
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
I	SHAREHOLDERS' FUNDS:						
	a) Capital	2651	2611	2643	2651	2611	2643
	b) Reserves and Surplus	167869	139267	151565	165083	136999	149137
	LOAN FUNDS	2137	4469	3285	2137	4469	3285
	DEFERRED TAX - NET	5240	5046	5190	4774	4510	4741
	TOTAL	177897	151393	162683	174645	148589	159806
	FIXED ASSETS	64669	61297	61342	64691	61315	61359
	INVESTMENTS	42155	28115	44186	42097	28056	44217
	CURRENT ASSETS, LOANS AND ADVANCES:						
	a) Inventories	50792	43216	47957	52978	45519	49850
	b) Sundry Debtors	21886	22847	23444	20180	21530	22320
	c) Cash and Bank Balances	1024	1425	1287	1476	1803	1646
	d) Other Current Assets	21	36	27	21	35	27
	e) Loans and Advances	11589	9110	10406	7579	5119	6555
	Less: CURRENT LIABILITIES AND PROVISIONS:						
	a) Liabilities	13772	14284	16324	13908	14416	16434
	b) Provisions	467	369	9642	469	372	9644
	NET CURRENT ASSETS	71073	61981	57155	67857	59218	54320
	MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	Nil	Nil	Nil	Nil	Nil	Nil
	TOTAL	177897	151393	162683	174645	148589	159806

NOTES:

1. The above results for the period ended 30th September 2010, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 9th November, 2010 and were subjected to “limited review” by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting notified under the Companies Act, 1956.
3. Exceptional item of Rs.5404 lakhs provided during the 1st quarter of last year towards tax liability of earlier years has been withdrawn as the relevant tax provisions have since been amended in Finance Act of 2010.
4. The company is implementing a project for setting up a new Unit called “DSN SEZ Unit” at Visakhapatnam at an estimated cost of Rs.200 crores.
5. During the current quarter, the company has allotted 3,87,095 equity shares of Rs.2/- each to the employees on exercise of their stock options.
6. The figures for the previous year/period have been reclassified/ regrouped, wherever necessary.
7. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.09.2010:
Opening: Nil, Received during the Quarter: 11, Resolved: 11, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 09-11-2010

Dr. Murali K. Divi
Chairman & Managing Director